Aura Biosciences, INC Form 4 insider transactions

Director Teresa Marie Bitetti acquired 21,000 shares of common stock and options for 29,000 shares of Aura Biosciences, Inc.

Mark Plavsic, Chief Technology Officer of Aura Biosciences, sold 2,151 shares of common stock at $7.75 to cover tax withholding obligations related to vesting restricted stock units.

Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences, sold 1,404 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences, sold 2,534 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Elisabet de los Pinos, CEO of Aura Biosciences, sold 20,221 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Elisabet de los Pinos, CEO of Aura Biosciences, reports acquisition of restricted stock units and stock options, along with a correction to a previous filing.

Mark Plavsic, Chief Technology Officer of Aura Biosciences, reports acquiring shares through a restricted stock unit award and disposing of shares, along with acquiring stock options.

Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences, reports the acquisition of shares and stock options, as detailed in a recent SEC Form 4 filing.

Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences, reports acquisition of stock and options.

Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences, reports the acquisition of shares through a restricted stock unit award and stock options, as well as the disposal of shares.

Aura Biosciences CEO, Elisabet de los Pinos, sold 15,955 shares of common stock to cover tax obligations related to vesting restricted stock units.

Aura Biosciences' Vice President of Finance, Amy Elazzouzi, sold 1,001 shares of common stock to cover tax obligations related to vesting restricted stock units.

Aura Biosciences' Chief Medical Officer, Janet Jill Hopkins, sold 11,822 shares of common stock to cover tax obligations related to vesting restricted stock units.

Elisabet de los Pinos, CEO of Aura Biosciences, sold 9,200 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Amy Elazzouzi, Vice President of Finance at Aura Biosciences, sold 553 shares of common stock on October 29, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Julie Feder, CFO of Aura Biosciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Elisabet de los Pinos, CEO of Aura Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Mark Plavsic, Chief Technology Officer of Aura Biosciences, sold 7,383 shares of common stock on October 16, 2024, at a price of $9.85 per share to cover tax withholding obligations related to vesting restricted stock units.

Elisabet de los Pinos, CEO of Aura Biosciences, exercised stock options to purchase 5,474 shares of common stock just before their expiration date.

Director Antony C. Mattessich acquired 10,500 shares of common stock and options to purchase 14,500 shares of common stock from Aura Biosciences through equity awards.

Director Sapna Srivastava acquired 10,500 shares of common stock and options for 14,500 shares of Aura Biosciences, Inc.

Director David Michael Johnson acquired shares and options in Aura Biosciences through a restricted stock unit (RSU) award and a stock option grant.

Aura Biosciences' General Counsel and Secretary, Conor Kilroy, acquired 96,000 shares of common stock and stock options for 144,000 shares on April 2, 2024.